Mgc030
Phase 1
Mgc030 is one of 22 therapeutic programs targeting Urothelial Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
21 competitors in Urothelial Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Padcev
PfizerPhase 3
Balversa
Johnson & JohnsonPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Imjudo
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
MEDI4736
AstraZenecaPhase 3
Adriamycin
PfizerPhase 2
Ninlaro
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Mgc030. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- MMacroGenics